Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Phase 2 Terminated 320 enrolled Pliant Therapeutics, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

Timeline

Start: 2023-11-16
Primary completion: 2025-04-04
Completion: 2025-04-04

Outcome

Outcome not reported

Stopped: “DSMB recommendation”

Publications

Wuyts WA, Lancaster L, Maher TM, Ryerson CJ, Kreuter M, Corte TJ, Valenzuela C, Barnes CN, Lefebvre EA, Cosgrove GP, Flaherty KR, Richeldi L, Cottin V. Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial. BMJ Open Respir Res. 2026 Mar 10;13(1):e002937. doi: 10.1136/bmjresp-2024-002937.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bexotegrast	Small molecule	160 mg	Oral
Subject	bexotegrast	Small molecule	320 mg	Oral